Low profile non-symmetrical bare alignment stents with graft

Information

  • Patent Grant
  • 8574284
  • Patent Number
    8,574,284
  • Date Filed
    Tuesday, May 26, 2009
    15 years ago
  • Date Issued
    Tuesday, November 5, 2013
    11 years ago
Abstract
A stent graft for use in a medical procedure to treat a dissection of a patient's ascending thoracic aorta. The stent graft includes bare alignment stents at least at a proximal end, and often with a stent at both ends, each stent having opposing sets of curved apices, where the curved section of one broader set of apices has a radius of curvature that is greater than the curved section of the other narrower set of apices. The proximal stent is flared in a manner such that its broad apices occupy a larger circumference around the stent than do its narrower apices, where this flared feature provides for anchoring engagement near the aortic root in a manner not interfering with the coronary arteries or the aortic valve.
Description
FIELD OF THE INVENTION

The present invention relates generally to stent grafts for use in body vessels to treat medical conditions. In particular, this invention relates to a flared asymmetric stent having opposing sets of curved apices, where the curved section of one set of apices has a radius of curvature that is greater than the curved section of the other set of apices, and may present a lower profile, better compliance with irregular vascular geometry, and higher sealing forces than conventional stents.


BACKGROUND

Stents may be inserted into an anatomical vessel or duct for various purposes. Stents may maintain or restore patency in a formerly blocked or constricted passageway, for example, following a balloon angioplasty procedure. Other stents may be used for different procedures, for example, stents placed in or about a graft have been used to hold the graft in an open configuration to treat an aneurysm. Additionally, stents coupled to one or both ends of a graft may extend proximally or distally away from the graft to engage a healthy portion of a vessel wall away from a diseased portion of an aneurysm to provide endovascular graft fixation.


Stents may be either self-expanding or balloon-expandable, or they can have characteristics of both types of stents. Various existing self-expanding and balloon-expandable stent designs and configurations comprise generally symmetrical end regions including one or more apices formed of nitinol or another alloy wire formed into a ring. The apices commonly comprise relatively acute bends or present somewhat pointed surfaces, which may facilitate compression of the stent to a relatively small delivery profile due to the tight bend of the apices. Although having this advantage, in some situations, such relatively acute or pointed apices may be undesirable, in particular in vessel anatomies that are curved or tortuous such as, for example, the thoracic aorta.


The thoracic aorta presents a challenging anatomy for stent grafts used to treat thoracic aneurysms or dissections. The thoracic aorta comprises a curve known as the aortic arch, which extends between the ascending thoracic aorta (closet to the heart) and the descending thoracic aorta (which extends toward the abdominal aorta). Thoracic stent grafts are used to exclude thoracic aortic aneurysms. A stent graft's ability to conform to the tortuous anatomy of the aortic arch is a major concern. Current designs sometimes lack the desired sealing ability at the proximal end of the stent graft (closest to the heart). Also, current thoracic devices present a relatively large profile which, with some patients' anatomies may be problematic. Finally, many current stents have relatively acute points that may prevent them from being used in the aortic arch for fear of undesirable interaction with the artery wall after an extended amount of time in the patient.


Therefore, a generally nonsymmetrical stent having at least one relatively rounded apex that is less invasive in an expanded state than stents with more acute apices may alleviate the above problems, while providing an improved compliance to the aortic arch and increased radial force if used as a sealing and/or alignment stent, as well as a desirable ability to be crimped to a readily introducible diameter.


As one particular example, type-A thoracic aortic dissection (TAD-A) is a condition in which the intimal layer of the ascending thoracic aorta develops a tear, allowing blood to flow into the layers of the aortic wall, causing the development of a medial or subintimal hematoma. TAD-A is associated with a strikingly high mortality rate (about one-fourth to one-half of victims die within the first 24-48 hours). The current treatment for TAD-A is open surgery, where the chest is opened, the aorta is clamped, and a vascular prosthesis is sewn in place. Operative mortality rate for this procedure may be around 10%. Endovascular treatment of TAD-B (which affects the descending thoracic aorta) has been effective in reducing short-term and longer term mortality. Treatment of TAD-A may offer benefits as well, but is challenged by the likelihood that a graft or stent graft in the ascending aorta may migrate proximally toward the heart or distally away from it due to the turbulence of blood flow and the motion associated with the heart beating, thereby blocking coronary or great arteries, respectively. Therefore, it is desirable to provide an endovascular device configured to address the anatomic challenges of the ascending thoracic aorta including preventing migration of the device.


SUMMARY

The present invention relates generally to stents for use in body vessels to treat medical conditions. In particular, this invention relates to a stent having opposing sets of curved apices, where the curved section of one set of apices has a radius of curvature that is greater than the curved section of the other set of apices, and may present a lower profile than conventional stents. This configuration presents an asymmetrical stent with a graft having one or more intermediate stents that may be symmetrical or asymmetrical and forming columnar support in a stent graft configured for treatment of a thoracic ascending aortic dissection. Specifically, embodiments of the presently-presented stent may maintain a low profile while improving compliance with highly tortuous anatomy (such as, for example, that found in the region of the thoracic aorta and particularly the aortic arch) while providing improved radial sealing force compared to some current devices. In another aspect, the presently-presented stent may provide support and spacing within the larger context of a stent or stent-graft device that will allow, for example, placement of ancillary stents and/or stent-grafts.


In one example, the present invention may include a stent that includes at least one proximal apex and at least one distal apex connected with the proximal apices by a plurality of generally straight portions; where each proximal apex includes a first curved portion and each distal apex comprises a second curved portion; where the first curved portion and the second curved portion each includes at least one radius of curvature, and the radius of curvature of at least one of the proximal apices is greater than the radius of curvature of at least one of the distal apices.


In another example, the present invention may include at least one wire formed into stent including a ring of alternating opposed, generally curved apices where a radius of curvature of a plurality of the apices in a first direction is greater than a radius of curvature of the apices in an opposite direction. In still another example a stent graft may include a bare alignment stent at each end, each of the alignment stents comprising an asymmetrical geometry with broadly-rounded or filleted bare apices such that the stent graft is configured and dimensioned for treatment of a thoracic ascending aorta dissection.


Advantageously, the rounded apices may provide atraumatic contact with a vessel, while the combination of more rounded and less rounded apices provides for a low-profile stent that includes desirable compressibility during introduction and desirable compliance and sealing profiles when deployed in a vessel.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention. Moreover, in the figures, like referenced numerals designate corresponding parts throughout the different views.



FIGS. 1-3 show different views of a symmetrical stent;



FIG. 4 depicts an example of an asymmetric stent;



FIG. 5 diagrammatically illustrates the asymmetrical radii of curvature of the stent of FIG. 4;



FIG. 6 shows the stent of FIG. 4 in a simulated artery;



FIG. 7 depicts another example of an asymmetric stent;



FIG. 8 diagrammatically illustrates the asymmetrical radii of curvature of yet another example of a stent;



FIG. 9 shows the stent of FIG. 8 in a simulated artery;



FIG. 10 shows an end view of still another example of an asymmetric stent;



FIG. 11 shows a side view of the stent of FIG. 10;



FIG. 12 is a top perspective view of the stent of FIG. 10;



FIG. 13 shows the stent of FIG. 10 in a simulated artery;



FIG. 14 is a partial perspective of a stent-graft incorporating the stent of FIG. 10;



FIG. 15 illustrates a side view of the stent-graft of FIG. 14;



FIGS. 16-18 show a stent-graft with side branches;



FIG. 19 is a side view of a stent-graft device configured for endovascular treatment of a thoracic aorta dissection;



FIG. 20A shows a stent graft embodiment configured for treating a dissection in the ascending thoracic aorta (TAD-A);



FIG. 20B shows the stent graft embodiment of FIG. 20A from an end perspective view;



FIG. 21A shows a patient aorta with a TAD-A;



FIG. 21B shows the TAD-A of FIG. 21A, treated with the stent graft of FIGS. 20A-20B; and



FIG. 22 shows a simulated thoracic aorta.





DETAILED DESCRIPTION OF THE PREFERRED EXAMPLES

The present invention relates generally to stents for use in body vessels to treat medical conditions. In particular, this invention relates to a novel asymmetric stent having opposing sets of curved apices, where the curved section of one set of apices has a radius of curvature that is greater than the curved section of the other set of apices, and may present a lower profile than conventional stents. The lower profile may present advantages for use in patients with particularly tortuous or small-diameter vessels.


In the present application, the term “proximal” refers to a direction that is generally closest to the heart during a medical procedure, while the term “distal” refers to a direction that is furthest from the heart during a medical procedure. Reference throughout is made to proximal and distal apices, but those of skill in the art will appreciate that the proximal-distal orientation of stents of the present invention may be reversed without exceeding the scope of the claims.


As shown in FIGS. 4-15, this novel stent is not symmetrical like many commercially available stents, in that the radius of curvature of the opposing proximal and distal apices is different between the top and bottom of the stent. The stents may be attached to either end of a stent graft to provide sealing and may be used internally or externally to the graft material to provide support to the graft.


The asymmetric stent may be configured such that, when used with a graft, it will provide a sufficiently strong radial force at the graft's end openings to hold the graft material open against the artery wall. Also, the stent is intended to be short in length so that the graft will include flexibility sufficient to accommodate a patient's anatomy. This combination of flexibility and strong radial force provides an improved seal between the graft and artery wall. In addition, enhanced flexibility is provided as well, particularly when one or more stents are used to provide short segments and better accommodate curves.



FIG. 1 shows a conventional stent 100, which has symmetrical apices 102, 103. Specifically, the proximal apices 102 and the distal apices 103 all have generally the same radii of curvature (r1), which is illustrated in graphic form in FIG. 2. FIG. 3 is adapted from an FEA contour simulation and shows the stent 100 in a simulated artery 110, where the stent 100 is 20% oversized. The proximal and distal apices 102, 103 (circled) exert little or no pressure against the artery wall 110, while an intermediate region 107 exerts a higher pressure to provide—in one example—a total radial sealing force of 0.178 lbf. This configuration may be crimped to 18 Fr (e.g., for introduction via a catheter), with a maximum bend strain in the apices 102, 103 of about 5.8%. When using, for example, a typical NiTi wire for the stent, it is desirable not to exceed 10-12% strain to avoid increased risk of deforming the wire or adversely affecting its durability.



FIGS. 4-7 show a first example of a non-symmetrical stent 200, which is formed as a wire ring that has non-symmetrical proximal and distal generally curved apex portions (apices) 202, 203 separated from each other by intermediate generally straight portions. Specifically, the distal apices 203 all have generally the same radii of curvature (rd) as each other, but the distal apices' radii of curvature are different from those of the proximal apices 202 (rp). The distal apices 203 (which may be attached to and generally covered by graft material in a stent graft as described below with reference to FIGS. 14-15) are generally narrowly rounded in a manner not dissimilar from a traditional z-stent, but the proximal apices 202 are more broadly rounded. The difference in the proximal and distal apices 202, 203 is illustrated in graphic form in FIG. 5. In the illustrated example, the rounded proximal apices 202 have a radius of curvature of 6.0 mm, while the narrower distal apices 202 have a radius of curvature of 1.0 mm. In certain examples of non-symmetrical stents of the present invention, the radius of curvature of the rounded proximal apices (measured in the manner shown in FIG. 5) may be from about 4 mm to about 9 mm, and the radius of curvature of the narrower distal apices may be from about 0.5 mm to about 1.5 mm.


In these and other examples, the ratio of the proximal apices' radius of curvature to the distal apices' radius of curvature may be about 2.6:1 to about 18:1, and desirably may be about 6:1. The outer circumference of the stent 200 preferably is generally consistent such that, in this configuration, a solid outer face around the stent 200 would form a cylinder, although the stent will most preferably provide compliance with a surface less smooth than a cylinder.



FIG. 6 is adapted from an FEA contour simulation and shows the stent 200 in a simulated artery 210, where the stent 200 is 20% oversized. The proximal and distal apices 202, 203 (circled) exert little or no pressure against the artery wall 210, while an intermediate region 204 (boxed) exerts a greater pressure to provide—in the illustrated example—a total radial sealing force of about 0.160 lbf. This configuration may be crimped to 18 Fr, with a maximum bend strain in the apices 202, 203 of about 6.5%.



FIG. 7 shows another non-symmetrical stent embodiment 250 that is very similar to the embodiment of FIGS. 4-6, but which has a shorter proximal-distal length. Each of the examples shown in FIGS. 4-7 may be manufactured in substantially the same manner as current z-stents, with a modification only of forming the proximal apices to include a greater radius of curvature than the distal apices.



FIGS. 8-9 illustrate another example of a non-symmetrical stent 300, which has a proximal “rounded roof shape” profile rather than the generally semicircular profile of the examples described above with reference to FIGS. 4-7. The profile of each proximal apex 302 includes a central fillet 302a and a pair of symmetrically opposed shoulder fillets 302b that may be generally equidistant from the central fillet 302a, or that may be disposed at varied distances therefrom. For the proximal apices of the stent 300, the central fillets 302a each have a radius of curvature of 1.0 mm, and the shoulder fillets 302b each have a fillet radius of curvature of 0.5 mm. The distal apices 304 have a radius of curvature of 1.0 mm. In another example having the rounded roof shape configuration (not shown), the central and shoulder fillets of proximal apices may each have the same radius of curvature such as, for example, 0.5 mm each, with distal apices also having a 0.5 mm radius of curvature. In other examples, the central and shoulder fillets 302a, 302b may each have a radius of curvature from about 0.5 mm to about 5 mm, and the distal apices may each have a radius of curvature of about 0.5 mm to about 1.5 mm. In another example having the rounded roof shape configuration (not shown), the ratio between the radii of curvature of the central and each shoulder fillet of the proximal apices may be about 3:1. FIG. 8 also shows three spans useful for describing desirable proportions in stent embodiments: “x” indicates the distance between the apical extremities of the shoulder fillets 302b, “y” indicates the distance between the tips of the distal apices 304, and “z” indicates the distance along a longitudinal axis between the tip of the distal apices 304 and the apical extremity of the proximal fillet 302a. Desirable embodiments may include an x:y ratio of about 1:3 to about 7:8 and a y:z ratio of about 1:1 to about 3:1. In yet another example (not shown), the filleted apices of this example may be combined with the generally semicircular apices of the example described with reference to FIGS. 4-7.



FIG. 9 is adapted from an FEA contour simulation and shows the stent 300 in a simulated artery 310, where the stent 300 is 20% oversized. The proximal and distal apices 302, 304 exert little or no pressure against the artery wall 310, while an intermediate region exerts a greater pressure to provide—in the illustrated example—a total radial sealing force of about 0.420 lbf. This configuration may be crimped to 18 Fr, with maximum bend strains in the apices that may be less than about 9% and preferably are less than about 10-12%. The greater radial sealing force of this example may provide advantages for stent placement and retention in certain circumstances as compared to existing z-stents.



FIGS. 10-13 illustrate another example of a non-symmetrical stent 400, which has an expanded “flower configuration” as shown in FIG. 10. Specifically, when the stent 400 is in an expanded configuration, a circumference (defined by a generally circular imaginary line) around the proximal broader/more-rounded apices 402 is greater than the circumference around the distal narrower/less-rounded apices 404, which is shown most clearly in FIGS. 11-14. In this configuration a solid outer face around an expanded stent 400 would form a frustum of a cone. This configuration may be manufactured in the same manner as the examples described above with reference to FIGS. 4-7 (i.e., producing a stent with a generally uniform outer circumference), with an added step that may include drawing the distal apices 404 into a smaller circumference upon suturing them to a smaller diameter graft material. Alternatively, or in addition, the stent 400 may be heat-set to impose the desired shape.



FIG. 13 is adapted from an FEA contour simulation and shows the stent 400 in a simulated artery 410, where the stent 400 is 20% oversized. Surprisingly, the contour of pressure distribution along proximal and distal apices 402, 404 as well as an intermediate region is generally uniform throughout the stent circumference. The illustrated configuration provides a total radial sealing force of about 0.187 lbf. This property of generally uniform pressure distribution may provide advantages in certain applications of providing a seal and/or presenting less abrasion of a vessel wall through graft material as compared to stents with less uniform pressure distribution.



FIGS. 14-15 show two different views of a stent graft 500 using a stent example 400 of the present invention described above with reference to FIGS. 10-13. The stent graft 500 is shown in an expanded state and may be configured for use in treating a thoracic aortic aneurysm. The stent 400 is disposed at the proximal end of a generally cylindrical graft sleeve 502, to which its distal apices 404 are secured by sutures 504. The stent graft 500 also includes a series of z-stents 510a-d disposed distally from the stent 400. The first z-stent 510a is attached to the inner circumference of the graft 502, and the other z-stents 510b-510d are attached to the outer diameter of the graft 502. The proximal end of the stent 400 extends beyond the proximal end of the graft in a manner that may facilitate anchoring the graft in a vessel of a patient (e.g., a blood vessel).


The rounded points on the stent may protrude from the graft material only a small amount as is shown in FIGS. 14-15. In this example, only a small portion of the bare wire will be exposed to the artery wall. These unique (larger radii) rounded points are far less likely to perforate the artery wall than sharper points of a different stent configuration. Advantageously, this asymmetric stent design will maximize the efficacy of the seal while preserving the condition of the artery wall. Specifically, the narrower stent apices will provide for desirable radial expansion/sealing force, and the broader rounded apices will provide for a desirably atraumatic contact with an artery wall.



FIGS. 16-18 show a stent-graft embodiment 600 that includes a non-symmetrical stent 602 having more broadly rounded proximal apices 604 and more narrowly rounded distal apices 606. The stent 602 is attached by sutures to the inner surface (not shown) or outer surface of a generally columnar graft 610, which includes other stents 608. A second layer of graft material 612 is also attached to the inner circumference of the graft 610 midway down its length and extends proximally through the inner circumference of the stent 602. It should be appreciated that this design may be advantageously used in a para-renal orientation as described below, including branched passages providing a patent path of fluid communication from the descending aorta with renal arteries.


As shown in the end view of FIG. 17, this construction provides a passage for branch structures 614 (that may be embodied, for example, as tubular or non-tubular stents, stent-grafts, shown here for the sake of illustration as generic tubular structures), which pass through the passage formed between the two layers 610, 612 and through an aperture 611 in the graft 610. The tubular structures 614 will advantageously be disposed generally transversely through the inner radius of the more broadly rounded proximal apices 604 of the stent 602, which provides atraumatic columnar support for the graft 610 as well as an anchor for the tubular structures 614. The stent-graft 600 may be particularly useful for treatment of an abdominal aortic aneurysm (AAA) that is immediately adjacent to, or that goes across, the renal arteries such that it has a short neck and lacks a contact area that is sufficient to create an effective proximal seal and avoid the proximal Type I endoleaks that may occur with some currently-available AAA stent-grafts. Those of skill in the art will appreciate that the stent-graft 600 will allow general occlusion of the AAA, while providing patent passage through the descending aorta and from the aorta to the renal arteries. Specifically, a stent-graft configured in the manner of the stent-graft embodiment 600, which includes a modular design that may include branch stents and/or stent-grafts, will allow a seal to be formed above the renal arteries and below the celiac and superior mesenteric arteries. Also, as shown in FIG. 16, a second non-symmetrical stent 622 may be placed adjacent the first non-symmetrical stent 602 in an opposite orientation that will provide additional atraumatic support for the branching tubular structures 614, which preferably provide patent fluid flow to branching arteries such as, for example, the renal arteries.



FIG. 19 shows a stent-graft device 700 configured for endovascular treatment of a thoracic aorta dissection. The device 700 includes a non-symmetrical alignment stent 702 attached to a first end of a tubular graft material 704. A sealing stent 706 is attached in the central lumenal graft space proximate the alignment stent 702. The sealing stent 706 preferably is configured with a high radial force to promote efficacious sealing of the graft material 704 against a vessel wall. A body stent 708 configured here as a z-stent is disposed on the exterior of the graft material 704 and preferably is configured to provide longitudinal and circumferential stability/columnar support for the graft material of the device 700, such that it will conform to the vasculature and resist buckling when deployed in torturous anatomy such as the ascending thoracic aorta. A bare cannula stent 710 (such as, for example, a cut nitinol stent) is attached in the tubular graft material 704 at the opposite end from the alignment stent 702. This cannula stent 710 preferably is a conformable kink-resistant stent that provides distal sealing and migration-resistance. In a deployment of the device 700 to treat an aortic dissection, the alignment stent 702 preferably will be disposed proximal (nearer the heart) relative to the vessel tear, with the graft material traversing the tear in a manner generally sealing it from blood flow. And, the distal cannula stent 710 will help conform to the vasculature and retain a seal for treatment of the dissection. One or more of the sealing stent 706, body stent 708, and bare stent 710 may include one or more barbed projections configured to help anchor the device 700.


In another embodiment, shown in FIGS. 20A-20B, non-symmetrical alignment stents 802, 804 may be used at the ends of a stent graft 800 configured to treat a TAD-A. FIG. 20A shows a side view of the stent graft 800, including two bare alignment stents 802, 804, with one disposed at each end (“bare” is used here to define that one end of each stent extends beyond any covering such as graft fabric). Each of the alignment stents 802, 804 preferably is configured with a flared, “flower-like” configuration of broader apices 806, 808 similar to that discussed above with reference to FIGS. 10-13, with at least one of its narrower apices secured to the graft material 810 (e.g., by a suture, adhesive, or being partially woven into the graft). Specifically, it is preferable that the broader apices 806, which are not attached to the graft material 810, are flared outward to provide a larger outer circumference than that of the generally tubular body formed by the graft material 810. In other words, an imaginary border circle around the broader apices 806, 808 of the alignment stents 802, 804 generally defines a circle having a larger outer diameter than a circle defined by the narrower apices, which are attached to the graft material 810. (It should be understood that the generally circular outer borer defined by the apices may be elliptical, oval, or another rounded general outline, without exceeding the definition of “generally circular” as defined herein).


The graft material 810 preferably is secured to one or more stents 812 along its length that may be symmetrical (e.g., z-type) stents or asymmetrical stents of a type discussed above and that are configured to provide columnar support and maintain an open lumen therethrough. The distance between the apices 806 and a proximal end of the graft material 810 most preferably is such that it will provide an open path for coronary blood flow. Specifically, it is preferable that a height H between the apices 806 and the proximal edge of the graft material 810 is equal to or less than a distance from an aortic root surface that is between a patient's aortic valve and a distal-most opening of that patient's coronary arteries immediately adjacent the aortic valve, as is explained below in greater detail. This height is easily controlled by specific determination of where the stent 802 is secured to the graft material 810. FIG. 20B shows an end perspective view of the stent graft 800 shown in FIG. 20A.


The height H for a specific patient's stent graft may be customized based upon echogenic and/or radiologic measurement of the dimensions of the patient's ascending aorta and its lumen. The expanded outermost diameter of the proximal and distal stents may be about 16 mm to about 57 mm. The outermost diameter of the graft body 810 may be about 16 mm to about 54 mm. And, the length of the entire device may be from about 8 cm to about 25 cm. Preferably, the length and outer diameters of the device 800 are configured and dimensioned to treat a dissection of the ascending thoracic aorta without proximal or distal migration, with particular configuration of the proximal stent 802 to engage the aorta at or distal of the aortic root. Preferably, the stents are NiTi stents and the graft fabric is a low-profile graft fabric, such that the device may collapse to about 16 Fr to about 18 Fr for introduction, which presents an added advantage over current devices, which typically collapse only to about 20 Fr or greater. The curvatures and proportions of the bare and/or intermediate stents may be the same as described for any of the embodiments shown in the other figures and/or discussed above herein.



FIG. 21A shows a TAD-A: the ascending aorta 850 extends distally/upward from the aortic valve 852 which opens from the left ventricle (not shown). Coronary arteries 854 branch off the ascending aorta 850 immediately distal of the valve 852. A dissection 856 is shown as having created a false lumen 858 proximal of the branching great vessels 890 (e.g., brachiocephalic, left common carotid, left subclavian arteries) along the aortic arch (transverse aorta). This aortic root region includes a concave proximal surface geometry near and around the coronary arteries 854. It should be appreciated that, to the extent this device is claimed within a patient body, no part of the patient's body is being claimed as an essential element including that anatomical variants between different patients should not be interpreted as limiting the scope of any claim herein.



FIG. 21B shows the TAD-A of FIG. 21A having been treated by a stent graft 800. The stent graft 800 has been placed in a location providing patent fluid flow away from and isolating the dissection 856. The apices 806 of the proximal-end stent 802 engage aortic root area tissue distal of the aortic valve 852 in the region of the coronary arteries 854. As described above with reference to FIG. 20A, the height H of these apices 806 is configured to provide for free, substantially uninhibited blood flow to and through the coronary arteries 854. As will be appreciated by those of skill in the art, the region being treated is subjected to movement, fluid pressure, and turbidity from blood flow. Anchoring of the flared proximal apices 806 in the natural concavity of the aortic root 860 will prevent proximal migration of the stent graft in a manner that could impair blood flow to/through the coronary arteries 854 and/or the proper functioning of the aortic valve 852. The height and general configuration of the apices 806 from the edge of the graft material 810 most preferably is configured to ensure that the graft material will not occlude the coronary arteries 854. Similarly, the flaring and relative position of apices 808 of the distal stent 804 will prevent distal migration that could impair blood flow to/through the great vessels 890. The distal stent 804 is shown anchored between the coronary arteries 854 and the great vessels 890 without impairing flow to any of them. The intermediate stents 812 (one or more of which may be barbed) preferably anchor the graft material against the aorta wall in a manner maintaining surface contact to isolate the dissection.


It should be appreciated that the stent graft 800 presents several advantages compared to the open-heart graft surgeries now used to treat TAD-A. The stent graft 800 can be placed using a minimally invasive procedure (e.g., Seldinger technique) rather than subjecting the patient to the risks and surgical trauma associated with open heart surgery. It will provide a patent path of fluid communication that preferably will isolate the dissection to decrease risk of it rupturing while not occluding the coronary or other arteries branching off from the aorta. It should be appreciated that, provided the inclusion of the flared configuration, virtually all of the characteristics of the other stent embodiments described above may be included in the stents 802, 804 of the stent graft 800, including differently proportioned, filleted, or other apical configurations. It should also be appreciated that a stent graft configuration as shown in FIG. 21B may be accomplished using two component stent-grafts, each having a single bare alignment stent (e.g., when a greater length is desirable, providing two stent grafts similar to that shown in FIG. 14, inserting the end of one inside the other such that the bare alignment stents are at opposite ends and intermediate stents cause the two grafts to engage securely together, where one or more of those intermediate stents may be barbed).


COMPARISON EXAMPLE ONE

A clear but surprising advantage of the present design over prior stent graft designs has been discovered, as used within a curvature similar to the ascending thoracic aorta. A clear tube 905 simulating the curvature of an ascending thoracic aorta was provided, as shown in FIG. 22, and was used in testing stent grafts (not shown) by placing a proximal stent-graft-end at the lowest extremity of the curve and pushing pressurized fluid through the tube (right to left, in FIG. 22, essentially a vertically inverted simulated thoracic ascending aorta). A prior art stent graft with a covered alignment stent in its proximal end, was oriented in a clear tube 905 simulating the curvature of an ascending thoracic aorta. A “leaky” space commonly exists around the proximal stent graft end and is termed the proximal normal gap (PNG), which is the gap between the inner curve 907 of the simulated aorta 905 and the surface of the proximal stent graft end aligned such that the outer/lower edge of the stent graft contacts the lowest inner surface 909 of the outer curve of the simulated aorta 905. For exemplary prior art stent grafts having a coated proximal alignment stent, the average PNG was 4.11 mm or greater. The PNG is important, because it is this gap that allows blood flow around the exterior of a stent graft device, which can exacerbate the dissection and/or can collapse the intermediate graft portion of the device, which is a known problem in existing prior art TAD-A devices. The positioning described simulates the orientation a stent graft is likely to assume in the thoracic aorta.


However, the surprising advantage conferred by the present design arose from use of a stent graft (e.g., stent graft 800 of the type claimed herein). The enhanced flexibility of the presently-claimed design provides a superior conformance that provides an average PNG of 0.89 mm, which is significantly lower than the prior art devices that were tested.


Stent examples of the present invention may be constructed of NiTi alloys or other materials presently known or yet to be developed, all within the scope of the present invention. The stents preferably are made from Nitinol wire and will therefore be MRI compatible. In another preferable embodiment, a stent may be made from a laser-cut Nitinol cannula, effectively rendering it a seamless or nearly-seamless wire-like construction. Nitinol's superelastic properties will facilitate the stents ability to be crimped down into a low profile delivery system.


Although various examples of the invention have been described, the invention is not to be restricted except in light of the attached claims and their equivalents. Moreover, the advantages described herein are not necessarily the only advantages of the invention and it is not necessarily expected that every example of the invention will achieve all of the advantages described. Different embodiments not expressly described herein including those with features combined in a different manner than expressly illustrated herein may be practiced within the scope of the present invention. For at least these reasons, this narrative description should not be construed as defining the invention; rather, the claims set forth and define the present invention.

Claims
  • 1. A stent graft configured for treatment of a thoracic ascending aortic dissection, the stent graft comprising: a proximal stent and a distal stent each including a plurality of narrower apices defining a generally circular first stent end and comprising first and second generally straight portions anda first curved portion disposed between the first and second straight portions and comprising a first radius of curvature; anda plurality of broader apices defining a generally circular second stent end and comprising third and fourth generally straight portions anda second curved portion disposed between the third and fourth straight portions and comprising a second radius of curvature that is greater than the first radius of curvature, andwhere at least one of the first and second generally straight portions is continuous with at least one of the third and fourth generally straight portions;a tubular graft material body secured to and extending between the proximal and distal stents, forming a patent fluid passage between them;where each of the stents is secured to the graft material such that its broader apices extend beyond an end of the tubular graft material body; andwhere an outer diameter defined by the broader apices of the generally circular second stent end is greater than an outer diameter defined by the narrower apices of the generally circular first stent end; andat least one intermediate stent secured to the graft material between the proximal and distal stents, the at least one intermediate stent providing columnar support to maintain an open geometry of the tubular graft material body,where the first radius of curvature is from about 0.5 mm to about 1.5 mm,where the second radius of curvature is from about 4 mm to about 9 mm, andwhere a ratio of the first radius of curvature to the second radius of curvature is about 1:2.6to about 1:18, andwhere each of the proximal stent and the distal stent comprises at least one uncovered region.
  • 2. The stent graft of claim 1 further comprising a plurality of intermediate stents.
  • 3. The stent graft of claim 1 where the first radius of curvature is about 1 mm, and the second radius of curvature is about 6 mm.
  • 4. The stent graft of claim 1 where the proximal stent comprises a portion of the broader apices configured and dimensioned to engage an aortic root surface between a patient aortic valve and a coronary artery.
  • 5. The stent graft of claim 4 configured such that a blood flow from the aortic valve to the coronary artery will be substantially uninhibited.
  • 6. The stent graft of claim 1, where the distal stent comprises a portion configured and dimensioned to engage an aortic surface distal of an ascending thoracic aortic dissection and proximal of a first great vessel branch.
  • 7. The stent graft of claim 1 where at least one of the proximal apices comprises first and second fillets disposed a distance from the second curved portion, the first fillet comprising a first fillet radius of curvature and the second fillet comprising a second fillet radius of curvature.
  • 8. The stent graft of claim 7 where the first fillet radius of curvature and the second fillet radius of curvature each have a radius of curvature of about 1 mm, and the first curved portion has a radius of curvature of about 0.5 mm.
  • 9. The stent graft of claim 7 where the ratio of the radius of curvature of the first curved portion to at least one of the first and second fillet radius of curvature is about 1:1 to about 1:10.
  • 10. The stent graft of claim 1, where at least one of the stents is secured to the graft using one or more sutures.
  • 11. The stent graft of claim 1, further comprising being disposed in the aorta of a patient.
  • 12. A stent graft configured for treatment of a thoracic ascending aortic dissection, the stent graft comprising: a bare proximal-end alignment stent;a tube of graft material secured to a distal portion of the proximal-end stent, the tube of graft material comprising at least one intermediate stent secured thereto in a manner providing columnar support;where the proximal-end stent includes a plurality of broader apices and a plurality of narrower apices connected with the broader apices by a plurality of generally straight portions; where each broader apex comprises a first curved portion and each narrower apex comprises a second curved portion;where the first curved portion and the second curved portion each comprises at least one radius of curvature, and the radius of curvature of at least one of the broader apices is greater than the radius of curvature of at least one of the narrower apices;where the proximal-end stent is flared such that its proximal apices are more distant from a longitudinal center axis of the graft material tube than its distal apices,where the radius of the narrower apices is from about 0.5 mm to about 1.5 mm,where the radius of curvature of the broader apices is from about 4 mm to about 9 mm, andwhere a ratio of the radius of curvature of the narrower apices to the radius of curvature of the broader apices is about 1:2.6 to about 1:18, andwhere the bare proximal-end alignment stent comprises at least one uncovered region.
  • 13. The stent graft of claim 12, further comprising a bare distal-end stent including a plurality of broader apices and a plurality of narrower apices connected with the broader apices by a plurality of generally straight portions; where each broader apex comprises a first curved portion and each narrower apex comprises a second curved portion;where the first curved portion and the second curved portion each comprises at least one radius of curvature, and the radius of curvature of at least one of the broader apices is greater than the radius of curvature of at least one of the narrower apices; andwhere the distal-end stent is flared such that its distal apices are more distant from a longitudinal center axis of the graft material tube than its proximal apices.
  • 14. The stent graft of claim 13, configured to include a collapsed outer diameter of about 16 Fr, an expanded outer diameter of the graft portion of about 16 mm to about 54 mm, and an expanded outer diameter of the bare proximal-end alignment stent of about 16 mm to about 57 mm.
  • 15. The stent graft of claim 13, further comprising being placed into an ascending thoracic aorta of a patient such that the bare proximal-end alignment stent is immediately adjacent to but does not significantly occlude or impair the function of the aortic valve and coronary arteries proximate the aortic valve.
  • 16. The stent graft of claim 15, where the distal-end stent is near but does not occlude arteries branching from an aortic arch of the patient.
  • 17. The stent of claim 1 where a ratio of the first radius of curvature to the second radius of curvature is about 1:6.
  • 18. The stent of claim 12 where a ratio of the radius of curvature of the narrower apices to the radius of curvature of the broader apices is about 1:6.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of pending U.S. application Ser. No. 12/332,904, filed Dec. 11, 2008, which claims priority to U.S. Prov. App. Ser. No. 61/016,753, filed Dec. 26, 2007, each of which is incorporated herein by reference in its entirety.

US Referenced Citations (114)
Number Name Date Kind
5258021 Duran Nov 1993 A
5292331 Boneau Mar 1994 A
5403341 Solar Apr 1995 A
5569295 Lam Oct 1996 A
5607468 Rogers et al. Mar 1997 A
5630829 Lauterjung May 1997 A
5674278 Boneau Oct 1997 A
5843164 Frantzen et al. Dec 1998 A
5855601 Bessler et al. Jan 1999 A
5906639 Rudnick et al. May 1999 A
5913897 Corso et al. Jun 1999 A
5961546 Robinson et al. Oct 1999 A
5993482 Chuter Nov 1999 A
6071307 Rhee et al. Jun 2000 A
6203569 Wijay Mar 2001 B1
6293966 Frantzen Sep 2001 B1
6296662 Caffey Oct 2001 B1
6348068 Campbell et al. Feb 2002 B1
6368345 Dehdashtian et al. Apr 2002 B1
6423090 Hancock Jul 2002 B1
6451051 Drasler et al. Sep 2002 B2
6539984 Lam Apr 2003 B2
6582458 White et al. Jun 2003 B1
6585757 Callol Jul 2003 B1
6616689 Ainsworth et al. Sep 2003 B1
6629994 Gomez et al. Oct 2003 B2
6635083 Cheng et al. Oct 2003 B1
6645242 Quinn Nov 2003 B1
6648911 Sirhan et al. Nov 2003 B1
6663661 Boneau Dec 2003 B2
6673102 Vonesh et al. Jan 2004 B1
6849088 Dehdashtian et al. Feb 2005 B2
6962604 Hijlkema Nov 2005 B2
7186263 Golds et al. Mar 2007 B2
7331992 Randall et al. Feb 2008 B2
7341598 Davidson et al. Mar 2008 B2
7407509 Greenberg et al. Aug 2008 B2
7473275 Marquez Jan 2009 B2
7615072 Rust et al. Nov 2009 B2
7758626 Kim et al. Jul 2010 B2
7766962 Quinn Aug 2010 B1
7794492 Ishimaru et al. Sep 2010 B2
7887580 Randall et al. Feb 2011 B2
8128678 Leewood et al. Mar 2012 B2
8333799 Bales et al. Dec 2012 B2
8348994 Leopold et al. Jan 2013 B2
8425586 Leopold et al. Apr 2013 B2
20020016627 Golds Feb 2002 A1
20020022877 Mueller et al. Feb 2002 A1
20030033003 Harrison et al. Feb 2003 A1
20030088305 Van Schie et al. May 2003 A1
20030125797 Chobotov et al. Jul 2003 A1
20030130720 DePalma et al. Jul 2003 A1
20030199967 Hartley et al. Oct 2003 A1
20040054396 Hartley et al. Mar 2004 A1
20040117003 Ouriel et al. Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040215316 Smalling Oct 2004 A1
20040215319 Berra et al. Oct 2004 A1
20040254625 Stephens et al. Dec 2004 A1
20050033406 Barnhart et al. Feb 2005 A1
20050049674 Berra et al. Mar 2005 A1
20050113905 Greenberg et al. May 2005 A1
20050131516 Greenhalgh Jun 2005 A1
20050154446 Phillips et al. Jul 2005 A1
20050159803 Lad et al. Jul 2005 A1
20050222671 Schaeffer et al. Oct 2005 A1
20050273155 Bahler et al. Dec 2005 A1
20060004436 Amarant et al. Jan 2006 A1
20060052860 Gomez et al. Mar 2006 A1
20060100695 Peacock et al. May 2006 A1
20060161243 Fearnot et al. Jul 2006 A1
20060190075 Jordan et al. Aug 2006 A1
20060247761 Greenberg et al. Nov 2006 A1
20060267247 Anukhin et al. Nov 2006 A1
20070027525 Ben-Muvhar Feb 2007 A1
20070055345 Arbefeuille Mar 2007 A1
20070055347 Arbefeuille Mar 2007 A1
20070067016 Jung Mar 2007 A1
20070073388 Krolik et al. Mar 2007 A1
20070135889 Moore et al. Jun 2007 A1
20070142894 Moore et al. Jun 2007 A1
20070163668 Arbefeuille et al. Jul 2007 A1
20070168019 Amplatz et al. Jul 2007 A1
20070179592 Schaeffer Aug 2007 A1
20070185560 Roeder et al. Aug 2007 A1
20070191927 Bowe et al. Aug 2007 A1
20070203566 Arbefeuille et al. Aug 2007 A1
20070208256 Marilla Sep 2007 A1
20070219620 Eells et al. Sep 2007 A1
20070219624 Brown et al. Sep 2007 A1
20070225797 Krivoruhko Sep 2007 A1
20070233220 Greenan Oct 2007 A1
20070244547 Greenan Oct 2007 A1
20070250152 Xiao et al. Oct 2007 A1
20070282433 Limon et al. Dec 2007 A1
20080033527 Nunez et al. Feb 2008 A1
20080086190 Ta Apr 2008 A1
20080109066 Quinn May 2008 A1
20080114441 Rust et al. May 2008 A1
20080119943 Armstrong et al. May 2008 A1
20080195191 Luo et al. Aug 2008 A1
20080269866 Hamer et al. Oct 2008 A1
20080281399 Hartley et al. Nov 2008 A1
20080319534 Birdsall et al. Dec 2008 A1
20090005856 Pappas et al. Jan 2009 A1
20090043376 Hamer et al. Feb 2009 A1
20090048663 Greenberg Feb 2009 A1
20090105809 Lee et al. Apr 2009 A1
20090149946 Dixon Jun 2009 A1
20090171437 Brocker et al. Jul 2009 A1
20090177270 Agnew et al. Jul 2009 A1
20120029624 Dierking et al. Feb 2012 A1
20120239136 Bruzzi Sep 2012 A1
Non-Patent Literature Citations (18)
Entry
Office Action for U.S. Appl. No. 12/622,351 dated Oct. 6, 2010, 12 pgs.
Response to Office Action for U.S. Appl. No. 12/622,351 filed Mar. 9, 2011, 15 pgs.
Office Action for U.S. Appl. No. 12/332,904 dated Oct. 4, 2010, 10 pgs.
Response to Office Action for U.S. Appl. No. 12/332,904 filed Mar. 4, 2011, 13 pgs.
Office Action dated Nov. 18, 2011 for U.S. Appl. No. 12/332,904, 15 pgs.
Interview Summary dated Jan. 24, 2012 for U.S. Appl. No. 12/332,904, 2 pgs.
Response to Office Action dated Feb. 21, 2012 for U.S. Appl. No. 12/332,904, 9 pgs.
Final Office Action for U.S. Appl. No. 12/332,904 dated Jan. 3, 2013, 6 pgs.
Final Office Action for U.S. Appl. No. 12/622,351 dated Jun. 10, 2011, 12 pgs.
Applicant Initiated Interview Summary for U.S. Appl. No. 12/622,351 dated Nov. 10, 2011, 5 pgs.
Office Action for U.S. Appl. No. 12/622,351 dated Dec. 1 , 2011, 16 pgs.
Interview Summary for U.S. Appl. No. 12/622,351 dated Jan. 24, 2012, 2pgs.
Amendment and Response for U.S. Appl. No. 12/622,351 dated Apr. 17, 2012, 11 pgs.
Office Action for U.S. Appl. No. 12/622,351 dated Jun. 27, 2012, 26 pgs.
Applicant Initiated Interview Request Form for U.S. Appl. No. 12/622,351 filed Nov. 2, 2012, 1 pg.
Applicant Initiated Interview Summary for U.S. Appl. No. 12/622,351 dated Nov. 8, 2012, 4 pgs.
Office Action Appendix for U.S. Appl. No. 12/622,351 dated Nov. 8, 2012, 3 pgs.
Amendment and response for U.S. Appl. No. 12/622,351 dated Dec. 26, 2012, 10 pgs.
Related Publications (1)
Number Date Country
20090306763 A1 Dec 2009 US
Provisional Applications (1)
Number Date Country
61016753 Dec 2007 US
Continuation in Parts (1)
Number Date Country
Parent 12332904 Dec 2008 US
Child 12472082 US